secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001104659-24-031908
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics shareholders approve 3x increase in authorized shares and reverse split
--------------------------------------------------------------------------------

- Authorized common shares raised from 425M to 1.2B (182% increase) to support financing.
- Approved reverse stock split at ratio 1:10 to 1:30; board to set exact ratio later.
- Proposals allowing issuance >19.99% of outstanding in private placement and note conversion passed.
- Amendment for officer exculpation under Delaware law did not pass.
- Re-elected directors: Gerd Auffarth, Julia Haller, Andong Huang, Lawrence Kenyon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924031908/0001104659-24-031908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924031908/tm248235d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-031908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer